Blueprint Medicines Corp (BPMC) is a biopharmaceutical company that focuses on discovering and developing precision therapies for patients with genomically defined diseases. The company's approach involves identifying the genetic drivers of disease and designing drugs that target these drivers.
BPMC has several drug candidates in clinical development, including avapritinib for gastrointestinal stromal tumors (GIST), BLU-554 for hepatocellular carcinoma (HCC), and pralsetinib (formerly BLU-667) for non-small cell lung cancer (NSCLC) and other solid tumors. The company has also partnered with Roche to develop BLU-782 for fibrodysplasia ossificans progressiva (FOP).
BPMC's lead product, Ayvakit (avapritinib), is an FDA-approved drug for the treatment of adult patients with GIST who have a PDGFRA exon 18 mutation, including PDGFRA D842V mutations. The drug is also in clinical development for other indications, including advanced systemic mastocytosis (SM), advanced and indolent SM, and fourth-line gastrointestinal stromal tumors (GIST).
In addition to its drug development programs, BPMC has a discovery research platform that uses proprietary chemistry and technology to identify and develop small molecule drugs against novel targets. The company is headquartered in Cambridge, Massachusetts, and was founded in 2011.
|
